Introduction
Diarrhoea and skin flushing are characteristic features of the carcinoid syndrome. The diarrhoea is thought to be caused mainly by 5-hydroxytryptamine (5-HT) (Grahame-Smith, 1972) whereas the possible causes of the flushing attacks include bradykinin (Oates et al., 1964) , prostaglandins (Sandler, Karim and Williams, 1968; Kaplan et al., 1973) 5-HT (Page and McCubbin, 1953) and noradrenaline and adrenaline (Schneckloth et al, 1957) . The tryptophan 5-hydroxylase inhibitor parachlorophenylalanine (PCPA) has been shown to alleviate carcinoid diarrhoea and concurrently lower the urinary excretion of 5-hydroxyindole acetic acid (5-HIAA) (Engelman, Lovenberg and Sjoerdsma, 1967) but is reported to be of little or no value in the treatment of carcinoid flushing (Grahame-Smith, 1972; Marks, 1979 range 14-20 ,ug/ml). Urinary tryptophan excretion (Denckla and Dewey, 1967) was also low, being between 1-3 and 1-7 mg/24 hr (normal around 4 mg/24 hr). A barium enema showed a filling defect in the caecum and an isotopic liver scan demonstrated multiple filling defects consistent with secondary deposits in both lobes of the liver. An echocardiogram was normal.
Treatment and response The diagnosis of carcinoid syndrome having been established, the patient underwent laparotomy during which the intestinal tumour was resected and all accessible hepatic secondary deposits removed. Postoperative recovery was uneventful. The patient continued taking codeine phosphate in doses ofup to 120 mg three times daily and methysergide 1 mg three times daily and for a year after the operation the diarrhoea and flushing attacks occurred once or twice a day. Subsequently both became more frequent, the diarrhoea being at times explosive and associated with a more severe colic than previously.
In an attempt to control the diarrhoea PCPA was started at a dose of 250 mg twice daily and increased over the course of 7 days to a total daily dose of 3-5 g (see Fig. 1 ). The codeine phosphate was stopped, but the methysergide continued. By the sixth day of treatment PCPA had abolished the flushing attacks but had no effect on the frequency or intensity of the diarrhoea. PCPA was stopped after 13 days of treatment because the patient developed profound depression and painful but not weak limb muscles. The serum muscle enzyme concentrations were not elevated. Both these complications resolved within a few days of stopping the drug by which time flushing had recurred at its pre-treatment frequency.
The mean urinary excretion rate of 5-HIAA (mg/24 hr± s.d.) was decreased by PCPA treatment from a pre-treatment value of 164 ± 36 to 72 ± 28; P<0 001 (see Fig. 1 ). By the ninth day after stopping PCPA the urinary 5-HIAA excretion rate had risen to 198 mg/24 hr. A comparison of mean fasting plasma tryptophan concentrations (Jug/ml±s.d.) and mean urinary tryptophan excretion rates (mg/24 hr ± s.d.) before and during PCPA treatment showed no significant differences: 8-2 ± 4-2 v. 8-9 ± 19 and 1[5 ± 0 2 v. 1 6 ± 04 respectively.
Discussion
In patients with the carcinoid syndrome it has been reported that flushing may occur independently of any increase in 5-HIAA urinary excretion rate (Davis and Rosenberg, 1961; Smith et al., 1964) , and that PCPA, whilst an effective treatment for carcinoid diarrhoea, does not lessen the flushing attacks (Grahame-Smith, 1972; Marks, 1979) . The patient reported here had abolition of flushing attacks and a marked lowering of the 5-HIAA urinary excretion rate whilst taking PCPA. It is possible that the patient was biochemically unusual with 5-HT causing flushing attacks but not diarrhoea or that vasoactive polypeptides other than 5-HT were responsible for causing this man's symptoms. The synthesis of bradykinin or prostaglandins, both of which have been implicated in causing carcinoid flushing (Oates et al., 1964; Sandler et al., 1968; Kaplan et al., 1973) may have been impaired by PCPA, although such effects have not been reported.
All five of the carcinoid patients reported by Engelman et al. (1967) had less diarrhoea when treated with PCPA but only one had less flushing. Three of the 5 developed psychiatric changes which included depression, hallucinations, confusion and anxiety. Our patient's depression began abruptly 9 days after starting PCPA and resolved quickly when the drug was stopped. PCPA crosses the blood-brain barrier (Lehmann, 1972) and may therefore have inhibited brain 5-HT synthesis. Such an effect might be expected to precipitate a mood change (van Praag, 1976) .
Muscle pains have been reported previously in association with the use of PCPA in patients with migraine (Sicuteri, Anselmi and Del Bianco, 1973) . The cause of the pains is unknown but Sicuteri et aL, (1973) suggested it may be related in part to depletion of 5-HT from the central nervous system. Low serum tryptophan concentrations in patients with the carcinoid syndrome were described by Lehmann (1972) . The fasting plasma tryptophan concentration and 24 hr urinary tryptophan excretion rate in our patient were both lower than found in normal but younger healthy controls (Green, et aL. 1980) . We have observed this in other patients with the carcinoid syndrome (unpublished observations) and these findings may be due to increased tryptophan utilisation by the tumour mass.
We do not know why our patient responded to PCPA in the way observed but this may have reflected the heterogeneous nature of the disease. PCPA may be of benefit to some patients with the carcinoid syndrome but its use may be limited by its adverse effects.
